Results 91 to 100 of about 4,272,652 (308)

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns   +10 more
wiley   +1 more source

Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform

open access: yesOrphanet Journal of Rare Diseases, 2020
Background The analysis of the main features of randomized controlled trials (RCTs) on ANCA-associated vasculitis (AAV) can inform future study design. Methods We searched within the International Clinical Trials Registry Platform all registered RCTs on ...
Michele Iudici   +4 more
doaj   +1 more source

Patients with Borderline Personality Disorder Not Participating in an RCT: Are They Different? [PDF]

open access: yes, 2010
Background: Despite the notion that randomized controlled trials are regarded as the gold standard in psychotherapy research, questions about their generalizability have been raised. This paper focuses on the differences between participants and eligible
Buchheim, Peter   +5 more
core   +1 more source

Clinical Virtual Simulation in Nursing Education: Randomized Controlled Trial

open access: yesJournal of Medical Internet Research, 2019
Background In the field of health care, knowledge and clinical reasoning are key with regard to quality and confidence in decision making. The development of knowledge and clinical reasoning is influenced not only by students’ intrinsic factors but also ...
J. Padilha   +4 more
semanticscholar   +1 more source

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

open access: yesMolecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel   +6 more
wiley   +1 more source

Pitfalls of Randomized Controlled Trials in Stroke: How Can We Do Better?

open access: yesStroke: Vascular and Interventional Neurology, 2023
Shadi Yaghi   +2 more
doaj   +1 more source

Simvastatin treatment does not affect serum Vitamin D concentrations in patients with dyslipidemia: A randomized double-blind placebo-controlled cross-over trial

open access: yesInternational Journal of Preventive Medicine, 2016
Background: Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are antihyperlipidemic drugs with an established efficacy in stabilizing atherosclerotic plaques and preventing atherogenesis and reducing cardiovascular events.
Mohsen Mazidi   +5 more
doaj   +1 more source

Qualitative evaluation of adherence therapy in Parkinson’s disease: a multidirectional model [PDF]

open access: yes, 2015
Background: Medication can control the symptoms of Parkinson’s disease (PD). Despite this, non-adherence with medication is prevalent in PD. Treatments for improving adherence with medication have been investigated in many chronic conditions, including ...
Daley, David   +4 more
core   +2 more sources

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova   +25 more
wiley   +1 more source

Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma

open access: yesJHEP Reports
Background & Aims: The RESORCE trial confirmed regorafenib as a second-line treatment for advanced hepatocellular carcinoma (HCC) in patients who tolerated sorafenib.
Keisuke Koroki   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy